Spine device companies are recovering from losses sustained earlier in the COVID-19 pandemic with growing revenues.
Here is a breakdown of key quarter results published by Zimmer Biomet, Stryker and Globus Medical this year, along with the year-over-year percentage change:
First quarter
Zimmer Biomet
Net sales: $1.8 billion (+3.6 percent)
Hip sales: $447 million (+3.3 percent)
Sports medicine, extremities, trauma, craniomaxillofacial and thoracic sales: $417.6 million (+9.6)
Knees sales: $614.3 (-2.3 percent)
Spine & dental sales: $246 million (+12.1 percent)
Stryker
Net sales: $4 billion (+10.2 percent)
Spine & neuro technology: $848 million (+14 percent)
Orthopedic sales: $1.5 billion (+21.4 percent)
Hip sales: $309 million (-2.2 percent)
Knee sales: $412 million (-4.5 percent)
Trauma & extremities: $640 million (+63.1 percent)
Globus Medical
Total sales: $227.3 million (+19.3 percent)
U.S. sales (including robotics): $193.3 million (+22 percent)
International sales: $34 million (+5.9 percent)
Net income: $45.3 million (+74.7 percent)
Second quarter
Zimmer Biomet
Net sales: $2 billion (+60.7 percent)
Hip sales: $474.6 million (+44 percent)
Sports medicine, extremities, trauma, craniomaxillofacial and thoracic sales: $462.1 million (+57.9 percent)
Knees sales: $665.6 (+77.5 percent)
Dental, spine sales: $263.5 million (73.1 percent)
Stryker
Net sales: $4.2 billion (+55.4 percent)
Spine & neuro technology: $918 million (+66.9 percent)
Orthopedic sales: $1.6 billion (+82.3 percent)
Hip sales: $353 million (+63.3 percent)
Knee sales: $474 million (+96.4 percent)
Trauma & extremities: $674 million (+104.2 percent)
Globus Medical
Total sales: $251 million (+68.6 percent)
U.S. sales (including robotics): $215.1 million (+71.9 percent)
International sales: $35.9 million (+51 percent)
Net income: $41.5 million (+299.4 percent)